{"id":410258,"date":"2021-01-07T08:03:17","date_gmt":"2021-01-07T13:03:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=410258"},"modified":"2021-01-07T08:03:17","modified_gmt":"2021-01-07T13:03:17","slug":"t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/","title":{"rendered":"T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer"},"content":{"rendered":"
\n

LEXINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — T2 Biosystems, Inc.\u00a0(NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, today announced that its Board of Directors has appointed Aparna Ahuja, MD, as Chief Medical Officer (CMO), effective immediately.<\/p>\n

In her new role, Dr. Ahuja will act as the company\u2019s key medical spokesperson providing leadership and strategic direction for all medical, clinical and scientific affairs activities for T2 Biosystems.<\/p>\n

\u201cI am excited to be joining the T2 Biosystems leadership team at this critical time when high-quality rapid diagnostics \u2013 especially for sepsis \u2013 are growing in importance as we continue to face mounting global health challenges, like managing antimicrobial resistance, rising health care expenses, secondary and co-infections associated with the COVID-19 virus,\u201d said Dr. Ahuja.<\/p>\n

Dr. Ahuja possesses extensive global experience in Laboratory Medicine and in the medical device and diagnostics industry. Most recently, she served as Worldwide Vice President, Medical Affairs at Becton Dickinson (NYSE:BDX), a leading global medical technology company. Prior to Becton Dickinson, Dr. Ahuja held a variety of roles in clinical practice, research and academia. She is an active member of the American Association of Clinical Chemistry (AACC), College of American Pathologists (CAP), American Society of Microbiology (ASM), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), and serves as President of AACC New Jersey section and Vice Chairholder of CLSI Expert Panel.<\/p>\n

\u201cI am confident that Aparna\u2019s extensive professional experience and passion for improving patient care through diagnostic technology will help to increase awareness and foster adoption of our technology,\u201d said John Sperzel, President and CEO at T2 Biosystems. \u201cShe has dedicated the entirety of her career to continuously improving diagnostic and testing capabilities, as well as patient outcomes, which is well-aligned with our mission and our focus on the rapid detection of sepsis-causing pathogens.\u201d<\/p>\n

T2 Biosystems is the Company behind the FDA-cleared T2Bacteria\u00ae Panel and T2Candida\u00ae Panel. These panels are the only FDA-cleared assays for the detection of sepsis-causing bacterial and fungal pathogens directly from whole blood in three to five hours, without the need to wait days for blood culture results. By providing quicker results, the panels enable clinicians to target therapy faster for their patients suspected of sepsis, often before the second dose of antimicrobial is administered, leading to better patient outcomes, improved antimicrobial stewardship, and reductions in length of stay in the hospital.<\/p>\n

Last year, the\u00a0Company received U.S. Food and Drug Administration\u00a0(FDA) Emergency Use Authorization (EUA) for its COVID-19 molecular diagnostic test, the T2SARS-CoV-2\u2122\u00a0Panel. The panel detects SARS-CoV-2, the virus responsible for COVID-19 infections, and provides results in under two hours utilizing a nasopharyngeal swab sample.<\/p>\n

\n About\u00a0T2 Biosystems<\/strong>
\n
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems\u2019 products include the T2Dx\u00ae Instrument, T2Candida\u00ae Panel, the T2Bacteria\u00ae Panel, the T2ResistanceTM<\/sup>\u00a0Panel, and the T2SARS-CoV-2\u2122 Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR\u00ae) technology. T2 Biosystems has an active pipeline of future products, including the T2CaurisTM<\/sup> Panel, and T2Lyme TM<\/sup> Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the ability of the Chief Medical Officer to impact on sepsis management and the adoption of T2 Biosystems\u2019 products, as well as statements that include the words \u201cexpect,\u201d \u201cintend,\u201d \u201cplan\u201d, \u201cbelieve\u201d, \u201cproject\u201d, \u201cforecast\u201d, \u201cestimate,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201canticipate,\u201d and similar statements of a future or forward looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials;\u00a0 (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes;\u00a0 (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission, or SEC, on March 16, 2020, and other filings the Company makes with the SEC from time to time.\u00a0 These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company\u2019s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.\u00a0 These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.<\/p>\n

\n Media Contact:<\/strong>
\n
Gina Kent,\u00a0Vault Communications
gkent@vaultcommunications.com<\/a>
610-455-2763<\/p>\n

\n Investor Contact:<\/strong>
\n
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com<\/a>
<\/a>415-937-5406<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

LEXINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — T2 Biosystems, Inc.\u00a0(NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, today announced that its Board of Directors has appointed Aparna Ahuja, MD, as Chief Medical Officer (CMO), effective immediately. In her new role, Dr. Ahuja will act as the company\u2019s key medical spokesperson providing leadership and strategic direction for all medical, clinical and scientific affairs activities for T2 Biosystems. \u201cI am excited to be joining the T2 Biosystems leadership team at this critical time when high-quality rapid diagnostics \u2013 especially for sepsis \u2013 are growing in importance as we continue to face mounting global health challenges, like managing antimicrobial resistance, rising health care expenses, secondary and co-infections associated with … <\/p>\n

Continue reading “T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-410258","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nT2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LEXINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — T2 Biosystems, Inc.\u00a0(NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, today announced that its Board of Directors has appointed Aparna Ahuja, MD, as Chief Medical Officer (CMO), effective immediately. In her new role, Dr. Ahuja will act as the company\u2019s key medical spokesperson providing leadership and strategic direction for all medical, clinical and scientific affairs activities for T2 Biosystems. \u201cI am excited to be joining the T2 Biosystems leadership team at this critical time when high-quality rapid diagnostics \u2013 especially for sepsis \u2013 are growing in importance as we continue to face mounting global health challenges, like managing antimicrobial resistance, rising health care expenses, secondary and co-infections associated with … Continue reading "T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-07T13:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTgxNiMzOTA3OTAwIzIwMDU4NDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer\",\"datePublished\":\"2021-01-07T13:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\\\/\"},\"wordCount\":1004,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTgxNiMzOTA3OTAwIzIwMDU4NDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\\\/\",\"name\":\"T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTgxNiMzOTA3OTAwIzIwMDU4NDQ=\",\"datePublished\":\"2021-01-07T13:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTgxNiMzOTA3OTAwIzIwMDU4NDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTgxNiMzOTA3OTAwIzIwMDU4NDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer - Market Newsdesk","og_description":"LEXINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — T2 Biosystems, Inc.\u00a0(NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, today announced that its Board of Directors has appointed Aparna Ahuja, MD, as Chief Medical Officer (CMO), effective immediately. In her new role, Dr. Ahuja will act as the company\u2019s key medical spokesperson providing leadership and strategic direction for all medical, clinical and scientific affairs activities for T2 Biosystems. \u201cI am excited to be joining the T2 Biosystems leadership team at this critical time when high-quality rapid diagnostics \u2013 especially for sepsis \u2013 are growing in importance as we continue to face mounting global health challenges, like managing antimicrobial resistance, rising health care expenses, secondary and co-infections associated with … Continue reading \"T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-07T13:03:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTgxNiMzOTA3OTAwIzIwMDU4NDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer","datePublished":"2021-01-07T13:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/"},"wordCount":1004,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTgxNiMzOTA3OTAwIzIwMDU4NDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/","name":"T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTgxNiMzOTA3OTAwIzIwMDU4NDQ=","datePublished":"2021-01-07T13:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTgxNiMzOTA3OTAwIzIwMDU4NDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTgxNiMzOTA3OTAwIzIwMDU4NDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/t2-biosystems-appoints-industry-expert-aparna-ahuja-md-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=410258"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410258\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=410258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=410258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=410258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}